Irrelevance of anti‑nAChR cytoplasmic loop antibody in the degree of myasthenia gravis

Lin,Ye; Song,Chen; Xu,Jiang; Yang,Yongxiang; Qin,Hang; Zhao,Cong; Lin,Jiaji; Liu,Rui; Li,Zhuyi

doi:10.3892/ijmm.2017.3074

Irrelevance of anti‑nAChR cytoplasmic loop antibody in the degree of myasthenia gravis

Authors:
- Ye Lin
- Chen Song
- Jiang Xu
- Yongxiang Yang
- Hang Qin
- Cong Zhao
- Jiaji Lin
- Rui Liu
- Zhuyi Li
View Affiliations

Affiliations: Department of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China
Published online on: July 19, 2017 https://doi.org/10.3892/ijmm.2017.3074
Pages: 931-939

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Anti‑nicotinic acetylcholine receptor (nAChR) antibody in myasthenia gravis (MG) usually refers to that against the extracellular domain (ECD) of nAChR. However, growing evidence has indicated that there also exists the nAChR antibody against the nAChR cytoplasmic loop (CL) in patients with MG. Some studies have demonstrated that the anti‑CL antibody may play a protective role in animal models of experimental autoimmune MG. However, to date, limited or no information is available as to whether anti‑CL antibody plays a beneficial role in patients with MG. In this, we examined the levels of anti‑CL and anti‑ECD antibodies in the sera of 76 patients with MG from the MG sample bank of our department, including 29 generalized MG (gMG) and 47 ocular MG (OMG) cases, as well as 40 healthy controls by radioimmunoassay. We also analyzed the correlation between anti‑CL antibody levels and the degree of severity in patients with MG. Our results revealed that among the 76 patients with MG, 61 serum samples (80.3%) were positive for anti‑ECD nAChR antibody, among which 38 (38/61, 62.3%) were positive for anti‑CL antibody. The levels of anti‑ECD antibodies in gMG were higher than those in OMG; however, the levels of anti‑CL antibodies in gMG were comparable with those in OMG. No clear correlation was observed between the anti‑ECD antibody levels and those of anti‑CL antibody. Taken together, our findings provide the first clinical evidence of the possibly different role of anti‑CL antibody in patients with MG compared to its role in animal models of MG. Anti‑CL antibody may not exert a beneficial effect in patients with MG, but may play an as yet udetermined role in the development of MG.

View Figures

View References

1	Lindstrom JM: Acetylcholine receptors and myasthenia. Muscle Nerve. 23:453–477. 2000. View Article : Google Scholar : PubMed/NCBI
2	Vincent A, Palace J and Hilton-Jones D: Myasthenia gravis. Lancet. 357:2122–2128. 2001. View Article : Google Scholar : PubMed/NCBI
3	Huijbers MG, Lipka AF, Plomp JJ, Niks EH, van der Maarel SM and Verschuuren JJ: Pathogenic immune mechanisms at the neuromuscular synapse: The role of specific antibody-binding epitopes in myasthenia gravis. J Intern Med. 275:12–26. 2014. View Article : Google Scholar
4	Karlin A: Emerging structure of the nicotinic acetylcholine receptors. Nat Rev Neurosci. 3:102–114. 2002. View Article : Google Scholar : PubMed/NCBI
5	Scarselli M, Spiga O, Ciutti A, Bernini A, Bracci L, Lelli B, Lozzi L, Calamandrei D, Di Maro D, Klein S and Niccolai N: NMR structure of alpha-bungarotoxin free and bound to a mimotope of the nicotinic acetylcholine receptor. Biochemistry. 41:1457–1463. 2002. View Article : Google Scholar : PubMed/NCBI
6	Lindstrom JM, Einarson BL, Lennon VA and Seybold ME: Pathological mechanisms in experimental autoimmune myasthenia gravis.I.Immunogenicity of syngeneic muscle acetylcholine receptor and quantitative extraction of receptor and antibody-receptor complexes from muscles of rats with experimental automimmune myasthenia gravis. J Exp Med. 144:726–738. 1976. View Article : Google Scholar : PubMed/NCBI
7	Tzartos SJ, Sophianos D and Efthimiadis A: Role of the main immunogenic region of acetylcholine receptor in myasthenia gravis. An Fab monoclonal antibody protects against antigenic modulation by human sera. J Immunol. 134:2343–2349. 1985.PubMed/NCBI
8	Das MK and Lindstrom J: The main immunogenic region of the nicotinic acetylcholine receptor: Interaction of monoclonal antibodies with synthetic peptides. Biochem Biophys Res Commun. 165:865–871. 1989. View Article : Google Scholar : PubMed/NCBI
9	Lindstrom J, Einarson B and Tzartos S: Production and assay of antibodies to acetylcholine receptors. Methods Enzymol. 74:432–460. 1981. View Article : Google Scholar : PubMed/NCBI
10	Gilhus NE and Verschuuren JJ: Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 14:1023–1036. 2015. View Article : Google Scholar : PubMed/NCBI
11	Luo J and Lindstrom J: Myasthenogenicity of the main immunogenic region and endogenous muscle nicotinic acetylcholine receptors. Autoimmunity. 45:245–252. 2012. View Article : Google Scholar :
12	Lindstrom J, Luo J and Kuryatov A: Myasthenia gravis and the tops and bottoms of AChRs: Antigenic structure of the MIR and specific immunosuppression of EAMG using AChR cytoplasmic domains. Ann N Y Acad Sci. 1132:29–41. 2008. View Article : Google Scholar : PubMed/NCBI
13	Luo J and Lindstrom J: AChR-specific immunosuppressive therapy of myasthenia gravis. Biochem Pharmacol. 97:609–619. 2015. View Article : Google Scholar : PubMed/NCBI
14	Tzartos SJ and Remoundos M: Detection of antibodies directed against the cytoplasmic region of the human acetylcholine receptor in sera from myasthenia gravis patients. Clin Exp Immunol. 116:146–152. 1999. View Article : Google Scholar : PubMed/NCBI
15	Luo J and Lindstrom J: Antigen-specific immunotherapeutic vaccine for experimental autoimmune myasthenia gravis. J Immunol. 193:5044–5055. 2014. View Article : Google Scholar : PubMed/NCBI
16	Matney SE and Huff DR: Diagnosis and treatment of myasthenia gravis. Consult Pharm. 22:239–248. 2007. View Article : Google Scholar : PubMed/NCBI
17	Jaretzki A III, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS and Sanders DB: Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 55:16–23. 2000. View Article : Google Scholar : PubMed/NCBI
18	Chang HW: Purification and characterization of acetylcholine receptor-I from Electrophorus electricus. Proc Natl Acad Sci USA. 71:2113–2117. 1974. View Article : Google Scholar : PubMed/NCBI
19	Greenwood FC, Hunter WM and Glover JS: The preparation of I-131-labelled human growth hormone of high specific radioactivity. Biochem J. 89:114–123. 1963. View Article : Google Scholar : PubMed/NCBI
20	Patrick J and Lindstrom J: Autoimmune response to acetylcholine receptor. Science. 180:871–872. 1973. View Article : Google Scholar : PubMed/NCBI
21	Tindall RS, Kent M and Wells L: A rapid immunoadsorbent radioimmunoassay for anti-acetylcholine receptor antibody. J Immunol Methods. 45:1–14. 1981. View Article : Google Scholar : PubMed/NCBI
22	Hayashi M, Takaoka T, Manabe K, Yoshinaga J and Kida K: Comparison of antibody titer to human and rat acetylcholine receptor in myasthenia gravis. Brain Dev. 17:38–41. 1995. View Article : Google Scholar : PubMed/NCBI
23	Oda K, Goto I, Kuroiwa Y, Onoue K and Ito Y: Myasthenia gravis: antibodies to acetylcholine receptor with human and rat antigens. Neurology. 30:543–546. 1980. View Article : Google Scholar : PubMed/NCBI
24	Kordas G, Lagoumintzis G, Sideris S, Poulas K and Tzartos SJ: Direct proof of the in vivo pathogenic role of the AChR autoanti-bodies from myasthenia gravis patients. PLoS One. 9:e1083272014. View Article : Google Scholar
25	Heyman B: Antibody feedback suppression: Towards a unifying concept? Immunol Lett. 68:41–45. 1999. View Article : Google Scholar : PubMed/NCBI
26	Heyman B: Feedback regulation by IgG antibodies. Immunol Lett. 88:157–161. 2003. View Article : Google Scholar : PubMed/NCBI
27	PLOS ONE Staff: Correction: Direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patients. PLoS One. 10:e01176732015. View Article : Google Scholar
28	Schürholz T, Kehne J, Gieselmann A and Neumann E: Functional reconstitution of the nicotinic acetylcholine receptor by CHAPS dialysis depends on the concentrations of salt, lipid, and protein. Biochemistry. 31:5067–5077. 1992. View Article : Google Scholar : PubMed/NCBI
29	Chang HW and Bock E: Factors influencing the stability of isolated acetylcholine receptor from Torpedo californica. Neurochem Int. 2C:269–280. 1980. View Article : Google Scholar : PubMed/NCBI
30	Tzartos SJ, Morel E, Efthimiadis A, Bustarret AF, D'Anglejan J, Drosos AA and Moutsopoulos HA: Fine antigenic specificities of antibodies in sera from patients with D-penicillamine-induced myasthenia gravis. Clin Exp Immunol. 74:80–86. 1988.PubMed/NCBI